Headlines about Akebia Therapeutics (NASDAQ:AKBA) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a news impact score of 0.03 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.6039178365883 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s scoring:
- An Eye on Stock Value – Akebia Therapeutics Inc (NASDAQ: AKBA) (stocksmarketcap.com)
- Akebia Therapeutics Inc. (AKBA) Expected to Post Quarterly Sales of $49.65 Million (americanbankingnews.com)
- Akebia Therapeutics Inc. (AKBA) Expected to Announce Earnings of -$0.68 Per Share (americanbankingnews.com)
- Akebia Therapeutics Inc. (AKBA) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Akebia (AKBA) Presents At H. C. Wainwright Global Life Sciences Conference – Slideshow (seekingalpha.com)
AKBA stock traded down $0.05 during mid-day trading on Tuesday, reaching $9.90. 99,869 shares of the company traded hands, compared to its average volume of 439,763. The firm has a market capitalization of $548.22, a PE ratio of -5.59 and a beta of 1.10. Akebia Therapeutics has a 52-week low of $9.00 and a 52-week high of $20.25.
Several brokerages have recently issued reports on AKBA. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 15th. BidaskClub lowered Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 15th. Mizuho reaffirmed a “buy” rating and set a $24.00 target price on shares of Akebia Therapeutics in a research report on Tuesday, March 13th. Finally, Piper Jaffray began coverage on Akebia Therapeutics in a research report on Monday, December 18th. They set an “overweight” rating and a $26.00 target price for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.20.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.